StocksMedium•18 November 2026•
1 min read
Capricor Therapeutics Awaits FDA Decision on Duchenne Therapy Deramiocel
Key Facts
1Capricor Therapeutics is awaiting the FDA's decision on its deramiocel therapy for Duchenne muscular dystrophy, scheduled for Nov. 22.
Capricor Therapeutics is awaiting the FDA's decision on its deramiocel therapy, which is scheduled for November 22, 2026. Benzinga reported that this regulatory deadline is a critical milestone for the company, as deramiocel is its lead cell therapy candidate for treating Duchenne muscular dystrophy.
CAPR closed at $8.41 on November 17, 2026, with the stock trading between a low of $8.21 and a high of $8.98 during that session. Investor focus remains on the upcoming regulatory outcome, which represents a primary catalyst for the company's lead product candidate.